Clinical trial
Treatment of Neuroendocrine Tumors (NETs) With Combination of Everolimus and Radiolabeled Somatostatin Analogue
NCT03629847 is registered in ClinicalTrials.gov with King Faisal Specialist Hospital & Research Center as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Treatment of Neuroendocrine Tumors (NETs) With Combination of Everolimus and Radiolabeled Somatostatin Analogue
- Lead sponsor
- King Faisal Specialist Hospital & Research Center
- Phase
- Phase 1/2
- Overall status
- Unknown status
- Start date
- December 31, 2012
- Completion date
- December 31, 2018
- Enrollment
- 30 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.